title: [Reversion of multidrug resistance by CIK in K562/ADR cells and its mechanism exploration].
abstract: OBJECTIVE
  To investigate the effects and mechanism of cytokine-induced killer (CIK) cells in reversing multidrug resistance (MDR) and increasing intracellular concentration of adriamycin (ADR) in the K562/ADR cells.
  
  
  METHODS
  Peripheral mononuclear cells (MNCs) were isolated from healthy donors and cultured with combined cytokines to generate CIK. The changes of cell phenotype and cytokines secretion of CIK were determined. K562/ADR cells were divided into three groups: ADR in combination CIK (group I), CIK alone (group II) and ADR alone (group III). The viability and proliferation of K562/ADR cells were assayed by MTT assay, the intracellular concentration of ADR and the expression of P-glycoproteins (P-gp) in K562/ADR cells by FCM.
  
  
  RESULTS
  The cytotoxicity of ADR in group I was higher than that in group II (P < 0.05). The cytotoxicity was increased with the E/T ratio increasing (P < 0.05) but had no relation with the concentration of ADR in group I (P > 0.05). The expression of P-gp was declined in group I and group II (P > 0.05). The intracellular concentration of ADR in group I was higher than that in group II (P < 0.05), and had no relation with the ADR concentration (P > 0.05).
  
  
  CONCLUSIONS
  Pre-treatment with CIK can increase the cytotoxicity and the intracellular concentration of ADR and decrease the expression of P-gp in K562/ADR cells in the ADR and CIK combination group. Acute leukemia patients would be most likely to benefit from the combination of chemotherapy and CIK therapy.
authors.affiliation: Department of Hematology, the First Central Hospital of Tianjin, Tianjin 300192, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Deng
authors.forename: Xue
authors.initials: X
authors.lastname: Bai
authors.forename: Xia
authors.initials: X
authors.lastname: Xiao
authors.forename: Yan
authors.initials: Y
authors.lastname: Jiang
authors.forename: Yu-ming
authors.initials: YM
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D018432:Drug Resistance, Multiple / Q000276:immunology*; D019008:Drug Resistance, Neoplasm / Q000276:immunology*; D006801:Humans; D020014:K562 Cells
chemical_list: D000970:Antineoplastic Agents